On 10th June 2019, Mr. Jacky Zhang, Executive Chairman of Beroni Group signed a letter of intent for strategic cooperation with Professor Takuya Tsunoda from Showa University at the China headquarters of Beroni Group in Tianjin. Sharing a common mission and purpose, both sides will work together on developing immunotherapy, clinical trials and new drugs.
Showa University was founded in 1928. For more than 90 years since its founding, Showa University has been adhering to the philosophy of “training doctors to do their best to contribute to human health” which was laid down by its founder, Kamijo Shusuke. It always strives to maintain the highest standards in all fields of education, research, and medical care in Japan. Showa University is now a comprehensive medical university with four faculties including School of Medicine, School of Dentistry, School of Pharmacy, School of Nursing and Rehabilitation.
Professor Takuya Tsunoda graduated from Wakayama Medical University in 1987. He also obtained a Ph.D. from Wakayama Medical University. He has worked in the field of cancer immunotherapy for more than 30 years and is now a leading pioneer in this field in Japan. Since 2000, Professor Takuya Tsunoda has been a lecturer at the Institute of Medicine of the University of Tokyo. He continued to work on clinical and scientific research. In 2006, Professor Takuya Tsunoda joined the University of Tokyo Biotech Venture Company. And from 2010, he has served as the President of Onco Therapy Science. Inc., a listed company in Japan, focusing on research and management in the field of immunotherapy for cancer treatment. He has been a professor in the School of Medical Oncology at Showa University since 2016.
Professor Takuya Tsunoda and his team of Medical Oncology has made many great achievements in using immunotherapy for cancer treatment and developing anti-cancer new drugs. His team is currently promoting the research on the combined treatment of breast cancer and medical research on anti-malignant drugs. Professor Takuya Tsunoda made a keynote speech at the “Beroni Group 2019 Scientific and Technological Strategy Symposium”.
“There are four therapies for cancer, surgery, radiotherapy, chemotherapy, and immunotherapy. The first three therapies target the cancer whereas immunotherapy target the immune system not the cancer. Immunotherapy can effectively slow down the pathology and spread of cancer. With the rapid development of medical science, cancer will not be looked upon as a life-threatening disease but just a chronic disease.” said Professor Takuya Tsunoda.
At the signing ceremony, Mr. Jacky Zhang, Executive Chairman of Beroni Group said: “We are very honored to be able to cooperate with Professor Takuya Tsunoda. Professor Tsunoda has vast experience in the fields of cancer immunotherapy and clinical trial. We welcome them to joining our Beroni Group Scientists’ Alliance for Precision Medicine. Through this agreement, we will cooperate in developing immunotherapy and new drugs.”
The collaboration between Beroni Group and Professor Takuya Tsunoda will enhance the Group’s core research and development capabilities and open up new paths for the Group in the use of immunotherapy for precise diagnosis and treatment of cancer. Beroni Group will take this opportunity to share and exchange our resources in scientific research, technology and talents with Professor Takuya Tsunoda’s team.